Tipifarnib in Subjects With Myelodysplastic Syndromes
Study sponsor: Kura Oncology, Inc. · KURA
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2018-08-28Actual
Enrollment · participants16Actual
Source updated2024-07-31Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.